



Opening Ceremony 開所式

Date & Time
日時 November 12 (Tue), 2024 14:00
2024年11月12日(火) 14:00

Venue
場所 Center for Cancer Immunotherapy and Immunobiology (CCII)
Bristol Myers Squibb Building, Nitori Hall (1F)
がん免疫総合研究センター Bristol Myers Squibb棟 ニトリホール(1F)

Invitation Only. Public online viewing via QR code.
現地出席は招待制です。オンライン視聴はこちら
Language: English and Japanese
言語: 日本語及び英語



Organizer: Graduate School of Medicine, Kyoto University
主催: 京都大学大学院医学研究科

Program

式次第

14:00	Opening Remarks	開会挨拶
14:30	Congratulatory Remarks & Greetings by Specially Invited Guests	来賓祝辞
15:15	- Break -	
15:45	Panel Discussion 1 Fundamental Breakthroughs in Cancer Research & Applications	パネルディスカッション1
16:30	Panel Discussion 2 Challenges Ahead for Cancer Research	パネルディスカッション2
17:15	Closing	閉会

1st CCII International Symposium on Immunotherapy and Immunobiology

Dates November 13 (Wed) – 15 (Fri), 2024

Venue Center for Cancer Immunotherapy and Immunobiology (CCII)
Bristol Myers Squibb Building, Nitori Hall (1F)

Admission free
Please register in advance via symposium website.
Language: English
Detailed program is on the reverse side.



Organizers:
Tasuku HONJO, Center for Cancer Immunotherapy and Immunobiology (CCII)
Sidonia FAGARASAN, Center for Cancer Immunotherapy and Immunobiology (CCII)

Speakers (Alphabetical order)

Vassiliki BOUSSIOTIS, Harvard Medical School
Kenji CHAMOTO, CCII, Kyoto University
Hilde CHEROUTRE, La Jolla Institute for Immunology
Hongbo CHI, St. Jude Children's Research Hospital
Cristina CURTIS, Stanford University
Ananda GOLDRATH, Allen Institute for Immunology
Silvio GUTKIND, University of California San Diego
Masatoshi HAGIWARA, Kyoto University
Tasuku HONJO, CCII, Kyoto University (Opening Remarks)
Juliana IDOYAGA, University of California San Diego
Carl JUNE, University of Pennsylvania
Nobuyuki KAKIUCHI, Kyoto University
Thomas KIPPS, University of California San Diego
Hiroyoshi NISHIKAWA, CCII, Kyoto University
Seishi OGAWA, Kyoto University
Hideho OKADA, University of California San Francisco
Klaus PANTEL, University Medical Center Hamburg-Eppendorf
Drew M. PARDOLL, Johns Hopkins Medicine
Eliane PIAGGIO, Curie Institute
Mamiko SAKATA-YANAGIMOTO, University of Tsukuba
Toshiro SATO, Keio University
Yuki SUGIURA, CCII, Kyoto University
Masaki TAJIMA, CCII, Kyoto University
Yosuke TOGASHI, Okayama University
Suzanne Louise TOPALIAN, Johns Hopkins Medicine
Hans Guido WENDEL, Memorial Sloan Kettering Cancer Center
Santiago ZELENAY, Cancer Research UK Manchester Institute
Baihao ZHANG, RIKEN
Laurence ZITVOGEL, Gustave Roussy Institute

Access & Contact

Yoshida Konoe-cho,
Sakyo-ku, Kyoto 606-8501
〒606-8501 京都市左京区
吉田近衛町
Website:
<https://ccii.med.kyoto-u.ac.jp>



Access
12 minutes walk from "Jingu-Marutamachi" Station (Keihan Railway)
1 minute walk from "Konoe-dori" Bus Stop (Kyoto City Bus, 201, 206)
京阪本線「神宮丸太町駅」より徒歩約12分/市バス201、206系統「近衛通」より徒歩1分

Contact
Secretariat of the CCII Opening Ceremony /
1st CCII International Symposium on Immunotherapy and Immunobiology
Congres Inc. Phone: +81-6-6292-6061 E-mail: ccii2024@congre.co.jp



<https://www.ccii2024.jp/>

1st CCII International Symposium on Immunotherapy and Immunobiology PROGRAM

Dates

November 13 (Wed) - 15 (Fri), 2024

Venue

Center for Cancer Immunotherapy and Immunobiology (CCII)
Bristol Myers Squibb Building, Nitori Hall (1F)

DAY1 Wednesday, November 13

Opening Remarks & Plenary Lecture

Chair: Nagahiro Minato, Kyoto University

9:00	9:20	Tasuku Honjo	CCII, Kyoto University	Opening remarks
9:20	10:05	Suzanne Louise Topalian	Johns Hopkins Medicine	Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy

Session 1: T Cell Therapy

Chair: Hiroyoshi Nishikawa, CCII, Kyoto University

10:05	10:45	Carl June	University of Pennsylvania	CAR T cells for cancer and beyond
10:45	11:25	Hilde Cheroutre	La Jolla Institute for Immunology	T cells naturally designed and selected to sense and eliminate cancer cells
11:25	11:40	Break		

Session 2: Myeloid Cells, PD-1 and Beyond

Chair: Osamu Takeuchi, Kyoto University

11:40	12:20	Vassiliki Boussiotis	Harvard Medical School	Induction and therapeutic exploitation of PD-1 tolerogenic function
12:20	13:00	Klaus Pantel	University Medical Center Hamburg-Eppendorf	Liquid biopsy: From discovery to clinical implementation
13:00	14:00	Break		

Session 3: Immunometabolism

Chair: Sidonia Fagarasan, CCII, Kyoto University

14:00	14:40	Drew M. Pardoll	Johns Hopkins Medicine	High dimensional dissection and therapeutic engineering of the tumor immune microenvironment
14:40	15:00	Yosuke Togashi	Okayama University	Novel immune evasion mechanisms involving mitochondria in the tumor microenvironment
15:00	15:20	Yuki Sugiura	CCII, Kyoto University	Exploration of volatile compounds in breath for development of the breath biopsy
15:20	15:35	Break		

Session 4: Cancer Antigens and Tolerance

Chair: Hideki Ueno, Kyoto University

15:35	16:15	Kenji Chamoto	CCII, Kyoto University	Molecular base of tumor neoantigens: intracellular expression of non-self MHC class I- and II-restricted chimeric epitopes reverses resistance to cancer immunotherapy
16:15	16:55	Eliane Piaggio	Curie Institute	Single-cell Treg profiling: new cancer therapies and insights into tumor-Treg biology
16:55	17:35	Hiroyoshi Nishikawa	CCII, Kyoto University	Cancer-mediated immunosuppression in the tumor microenvironment identified by immuno-genomic analyses

DAY2 Thursday, November 14

Session 5: Novel Therapeutics for Cancer

Chair: Silvio Gutkind, UC San Diego

9:00	9:40	Thomas Kipps	UC San Diego	Targeting cancer stemness
9:40	10:20	Masatoshi Hagiwara	Kyoto University	Chemical induction of splice-neoantigens enhances anti- tumor immunity and immunotherapy response
10:20	11:00	Juliana Idoyaga	UC San Diego	Monocyte fate during conformal radiotherapy controls therapeutic outcome
11:00	11:15	Break		

Session 6: Immunotherapy for CNS, Head and Neck Cancer

Chair: Masatoshi Hagiwara, Kyoto University

11:15	11:55	Hideho Okada	UC San Francisco	Development of immunotherapy strategies for brain tumors
11:55	12:35	Silvio Gutkind	UC San Diego	Novel immunotherapy targets: the druggable immune GPCRome and new immune-evasive cancer drivers
12:35	13:45	Break		

Session 7: Inflammation, Metabolism and Tumor Immunity

Chair: Thiago Carvalho

13:45	14:25	Santiago Zelenay	Cancer Research UK Manchester Institute	The dual role of inflammation in cancer immunity
14:25	15:05	Cristina Curtis	Stanford University	Germline genetics, host immunity and the microenvironment in cancer progression and immunotherapy response
15:05	15:25	Masaki Tajima	CCII, Kyoto University	Past history of high-fat diet causes persistent susceptibility to ferroptosis in CD8 T cells
15:25	15:45	Baihao Zhang	RIKEN	Organic osmolyte-mediated adaptations critical for immune homeostasis and T-cell mediated anti-tumor responses
15:45	16:00	Break		

Session 8: CD8 T Cells Biology

Chair: Mamiko Sakata-Yanagimoto, Tsukuba University

16:00	16:40	Ananda Goldrath	Allen Institute for Immunology	Functional diversity of memory CD8 T cells is spatiotemporally imprinted
16:40	17:20	Hongbo Chi	St. Jude Children's Research Hospital	Functional genomics and systems Immunology in mapping the metabolic basis of cancer immunity
17:45	18:30	Poster Session		

DAY3 Friday, November 15

Session 9: Tumor Diversity, Susceptibility and Resistance I

Chair: Yasuyuki Fujita, Kyoto University

9:00	9:40	Seishi Ogawa	Kyoto University	Somatic mosaicism and cancer
9:40	10:20	Hans Guido Wendel	Memorial Sloan Kettering Cancer Center	Towards therapies that are designed to exploit biological cancer vulnerabilities
10:20	10:35	Break		

Session 10: Tumor Diversity, Susceptibility and Resistance II

Chair: Seishi Ogawa, Kyoto University

10:35	11:15	Laurence Zitvogel	Gustave Roussy Institute	The dirty secrets of cancer immunology: links between gut microbiota and tumor immunosurveillance
11:15	11:55	Toshiro Sato	Keio University	Understanding of GI cancer initiation and progression using organoids
11:55	12:15	Nobuyuki Kakiuchi	Kyoto University	Clonal evolution from normal cells to cancer
12:15	12:35	Mamiko Sakata-Yanagimoto	University of Tsukuba	Immune cell with somatic mutations regulate tumor microenvironments
12:35	12:45	Closing remarks		